Journey Medical Up 21% on Rosacea-Drug Data
13 Junho 2023 - 3:15PM
Dow Jones News
By Josh Beckerman
Shares of Journey Medical were up 21%, to $2.03, as it reported
favorable topline Phase 1 study data for a papulopustular rosacea
treatment it is developing in collaboration with Dr. Reddy's
Laboratories.
Journey Medical said it is "very pleased" with the results for
DFD-29, which indicate that it can be safely used for up to 16
weeks with no significant risk of microbiota suppression or
development of resistance.
The company expects topline data from Phase 3 trials in June,
with a New Drug Application filing expected in the second half of
2023.
Journey Medical was founded by Fortress Biotech.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 13, 2023 14:00 ET (18:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Dr Reddys Laboratories (NYSE:RDY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Dr Reddys Laboratories (NYSE:RDY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024